Review of the cases on the implementation of drug patent compulsory license from the international perspectiveCAO Lei, LIU Zhao, ZHAO Kun, LIU Yue-hua1441-1448
The evolution of patent examination criteria for medical use inventions in Europe and comparisons of examination practices between Europe and ChinaWU Li, XUE Yang1449-1455
Considerations on the estimation of the starting dose design for a new drug in first-in-human studyZHANG Feng-qin, SUN Tao, WANG Hai-xue, WANG Qing-li1456-1463
Non-inferiority clinical trial: summary and considerationLI Xin-xu, ZHOU Jun, GAO Li-li, WANG Jun1469-1477
Regulatory factors of PD-1 expression associated with cancer immunotherapyHE Qing, GAO Hua, WANG Jun-zhi1478-1484
Cardiotoxicity assessment of cinobufotalin injectionLI Min, HUANG Li-hua, SHAO Shu-ming, CUI Tian-tian, HUANG Ming-shu, WANG Xi-jie, LI Hua, MA Jing1485-1494
Potential biosafety risks of typical dual-use biotechnologyZHANG Xin, WANG Ying, LIU Jing, LI Ping-ping, SUN Yan-rong1495-1500
Policy evaluation of biomedical industry based on PMC indexXU Li-ying, QIAO Han, LI Xu, CHU Shu-zhen1501-1507
The pharmacological effect, application prospect and pharmaceutical monitoring of remdesivirZHAI Li-jie, ZHAO Zhi-gang1508-1513